DYN

Dyne Therapeutics (DYN)

About Dyne Therapeutics (DYN)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Details

Daily high
$33.94
Daily low
$32.42
Price at open
$32.61
52 Week High
$47.45
52 Week Low
$6.40
Market cap
3.4B
Dividend yield
0.00%
Volume
682,436
Avg. volume
1.2M
P/E ratio
-9.39

Dyne Therapeutics News

Details

Daily high
$33.94
Daily low
$32.42
Price at open
$32.61
52 Week High
$47.45
52 Week Low
$6.40
Market cap
3.4B
Dividend yield
0.00%
Volume
682,436
Avg. volume
1.2M
P/E ratio
-9.39